Nuformix plc (LON:NFX – Get Free Report)’s share price rose 10% during mid-day trading on Wednesday. The company traded as high as GBX 0.11 and last traded at GBX 0.11. 12,136,803 shares were traded during trading, a decline of 58% from the average session volume of 28,948,861 shares. The stock had previously closed at GBX 0.10.
Nuformix Stock Performance
The stock has a market capitalization of £2.87 million, a P/E ratio of -3.75 and a beta of 1.53. The firm’s fifty day simple moving average is GBX 0.14 and its 200 day simple moving average is GBX 0.16.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Articles
- Five stocks we like better than Nuformix
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
- Synchrony Aces The Quarter As Credit Fears Fade
- Higher Rates Are Sending Investors to These 3 Dividend Kings
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
